MA49822A - Combinaison pharmaceutique comprenant du ponesimod - Google Patents
Combinaison pharmaceutique comprenant du ponesimodInfo
- Publication number
- MA49822A MA49822A MA049822A MA49822A MA49822A MA 49822 A MA49822 A MA 49822A MA 049822 A MA049822 A MA 049822A MA 49822 A MA49822 A MA 49822A MA 49822 A MA49822 A MA 49822A
- Authority
- MA
- Morocco
- Prior art keywords
- ponesimod
- pharmaceutical combination
- combination including
- pharmaceutical
- including ponesimod
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2017055994 | 2017-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49822A true MA49822A (fr) | 2020-06-17 |
Family
ID=61655772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049822A MA49822A (fr) | 2017-03-14 | 2018-03-13 | Combinaison pharmaceutique comprenant du ponesimod |
Country Status (24)
Country | Link |
---|---|
US (2) | US11723896B2 (fr) |
EP (1) | EP3595657A1 (fr) |
JP (2) | JP7281406B2 (fr) |
KR (1) | KR102574562B1 (fr) |
CN (1) | CN110381942B (fr) |
AU (2) | AU2018233109B2 (fr) |
BR (1) | BR112019018894A2 (fr) |
CA (1) | CA3056301A1 (fr) |
CL (1) | CL2019002525A1 (fr) |
CO (1) | CO2019008510A2 (fr) |
CR (1) | CR20190464A (fr) |
DO (1) | DOP2019000257A (fr) |
EA (1) | EA201992117A1 (fr) |
EC (1) | ECSP19073317A (fr) |
IL (1) | IL269239B2 (fr) |
JO (1) | JOP20190207A1 (fr) |
MA (1) | MA49822A (fr) |
MX (1) | MX2019010874A (fr) |
NI (1) | NI201900092A (fr) |
PE (1) | PE20191489A1 (fr) |
PH (1) | PH12019502110A1 (fr) |
SG (1) | SG11201907308UA (fr) |
UA (1) | UA125756C2 (fr) |
WO (1) | WO2018167030A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL178596C (nl) | 1975-06-05 | 1986-04-16 | Hoechst Ag | Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden. |
DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
HUP0301865A3 (en) * | 2000-02-15 | 2005-12-28 | Teva Pharma | A method for synthesizing leflunomide |
PT1381356E (pt) | 2001-04-05 | 2008-07-24 | Aventis Pharma Inc | Utilização de (4' -trifluorometilfenil) - amida do ácido (z) -2- ciano-3-hidroxi-but-2-enóico para tratamento da esclerose múltipla |
GB0123571D0 (en) * | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
US6894184B2 (en) | 2003-03-18 | 2005-05-17 | Aventis Pharma Deutschland Gmbh | Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides |
EP2295418A1 (fr) | 2003-11-21 | 2011-03-16 | Actelion Pharmaceuticals Ltd. | Dérivés de 5-(benz-(z)-ylidène)-thiazolidin-4-one comme agents immunosuppresseurs |
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
CA2584655A1 (fr) * | 2004-10-19 | 2006-04-27 | Aventis Pharmaceuticals Inc. | Emploi du (4'-trifluoromethylphenyl)amide de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique dans le traitement d'affections abdominales inflammatoires |
DE102006017896A1 (de) | 2006-04-13 | 2007-10-25 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Leflunomid enthaltende pharmazeutische Zusammensetzungen |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
CN101541772B (zh) | 2006-11-23 | 2013-04-17 | 埃科特莱茵药品有限公司 | 一种制备2-亚氨基-四氢噻唑-4-酮衍生物的新方法 |
SI2278960T2 (sl) | 2008-03-17 | 2020-02-28 | Actelion Pharmaceuticals Ltd. | Režim odmerjanja za selektivni agonist receptorja sip1 |
GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
US20120172427A1 (en) | 2009-09-18 | 2012-07-05 | Sanofi | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability |
EP2598126A2 (fr) | 2010-07-30 | 2013-06-05 | Saint Louis University | Méthodes de traitement de la douleur |
AR082436A1 (es) | 2010-08-02 | 2012-12-05 | Sanofi Aventis Us Llc | Uso de teriflunomida para tratar la esclerosis multiple |
EP2692343A1 (fr) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Polythérapie pour le traitement de la sclérose en plaques |
DK2885266T3 (da) | 2012-08-17 | 2020-06-08 | Actelion Pharmaceuticals Ltd | Fremgangsmåde til fremstilling af (2z,5z)-5-(3-chlor-4-((r)-2,3-dihydroxypropoxy)benzyliden)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-on og mellemprodukt, der anvendes i fremgangsmåden |
WO2016079687A1 (fr) | 2014-11-18 | 2016-05-26 | Lupin Limited | Composition pharmaceutique orale de tériflunomide |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
US10220023B2 (en) * | 2014-12-11 | 2019-03-05 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective S1P1 receptor agonist |
US20180185308A1 (en) | 2015-06-18 | 2018-07-05 | Matinas Biopharma Nanotechnologies, Inc. | Compositions and methods for treating inflammatory disease or conditions |
-
2017
- 2017-06-16 JO JOP/2019/0207A patent/JOP20190207A1/ar unknown
-
2018
- 2018-03-13 SG SG11201907308UA patent/SG11201907308UA/en unknown
- 2018-03-13 CR CR20190464A patent/CR20190464A/es unknown
- 2018-03-13 WO PCT/EP2018/056185 patent/WO2018167030A1/fr unknown
- 2018-03-13 US US16/494,163 patent/US11723896B2/en active Active
- 2018-03-13 AU AU2018233109A patent/AU2018233109B2/en active Active
- 2018-03-13 JP JP2019549459A patent/JP7281406B2/ja active Active
- 2018-03-13 CN CN201880017102.0A patent/CN110381942B/zh active Active
- 2018-03-13 MA MA049822A patent/MA49822A/fr unknown
- 2018-03-13 BR BR112019018894A patent/BR112019018894A2/pt active Search and Examination
- 2018-03-13 UA UAA201910123A patent/UA125756C2/uk unknown
- 2018-03-13 PE PE2019001845A patent/PE20191489A1/es unknown
- 2018-03-13 KR KR1020197026599A patent/KR102574562B1/ko active IP Right Grant
- 2018-03-13 CA CA3056301A patent/CA3056301A1/fr active Pending
- 2018-03-13 EP EP18711299.0A patent/EP3595657A1/fr active Pending
- 2018-03-13 MX MX2019010874A patent/MX2019010874A/es unknown
- 2018-03-13 EA EA201992117A patent/EA201992117A1/ru unknown
-
2019
- 2019-08-05 CO CONC2019/0008510A patent/CO2019008510A2/es unknown
- 2019-09-03 CL CL2019002525A patent/CL2019002525A1/es unknown
- 2019-09-10 IL IL269239A patent/IL269239B2/en unknown
- 2019-09-11 NI NI201900092A patent/NI201900092A/es unknown
- 2019-09-13 PH PH12019502110A patent/PH12019502110A1/en unknown
- 2019-10-08 DO DO2019000257A patent/DOP2019000257A/es unknown
- 2019-10-10 EC ECSENADI201973317A patent/ECSP19073317A/es unknown
-
2022
- 2022-12-21 JP JP2022204487A patent/JP2023030091A/ja active Pending
-
2023
- 2023-06-27 US US18/341,853 patent/US20240139161A1/en active Pending
- 2023-11-29 AU AU2023274118A patent/AU2023274118A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53243A (fr) | Compositions comprenant une combinaison de ipilimumab et nivolumab | |
DK3529248T3 (da) | Farmaceutiske sammensætninger | |
BR112018009951A2 (pt) | fármaco oftálmico | |
DK3479819T3 (da) | Stabilt væskeformigt farmaceutisk præparat | |
MA47816A (fr) | Composition pharmaceutique comprenant du sélexipag | |
MA46334A (fr) | Composition pharmaceutique liquide | |
DK3474804T3 (da) | Medicinsk forbinding | |
DK3634377T3 (da) | Farmaceutisk formulering | |
MA50541A (fr) | Formulations pharmaceutiques | |
DK3529240T3 (da) | Farmaceutiske forbindelser | |
DK3532029T3 (da) | Flydende farmaceutisk sammensætning | |
ES2972844T3 (es) | Preparación farmacéutica | |
MA43705A (fr) | Formulation pharmaceutique | |
MA46867A (fr) | Formulations pharmaceutiques | |
MA49822A (fr) | Combinaison pharmaceutique comprenant du ponesimod | |
MA45187A (fr) | Combinaisons pharmaceutiques | |
MA47516A (fr) | Composition pharmaceutique | |
MA49837A (fr) | Compositions pharmaceutiques | |
MA49977A (fr) | Combinaisons pharmaceutiques comprenant un anticorps anti-ly75 | |
DK3474803T3 (da) | Medicinsk forbinding | |
MA44079A (fr) | Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine | |
DK3601277T3 (da) | Farmaceutisk formulering | |
MA45126A (fr) | Formulation pharmaceutique antifongique | |
DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning | |
DK3519025T3 (da) | Indgivelsesanordning |